FINHUB Insights

JNJ · Q2 FY25 · Mar 31 – Jun 29, 2025

Johnson & Johnson Q2 FY25: where the revenue came from and where it went

Johnson & Johnson Q2 FY25: revenue $23.7B (+6% year over year). Net profit $5.5B. Largest cohort Innovative Medicine $15.2B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31 – Jun 29, 2025
Reported
Jul 24, 2025 10-Q
Sankey diagram of Johnson & Johnson's income statement for Q2 FY25: revenue of $23.7 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$23.7B +6% year over year
Gross profit$16.1B 68% margin
Operating profit$6.7B 28% margin
Net profit$5.5B 23% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 29, 2025).
ItemValueShare of revenueYear over year
Revenue 23.7 100% +6%
Innovative Medicine 15.2 64% +5%
Med Tech 8.5 36% +7%
Cost of revenue−7.632%
Gross profit16.168% margin−2pp
SG&A−5.925%−1pp
Other−3.515%+0pp
Operating profit6.728% margin+0pp
Tax−1
Interest & other costs−0.2
Net profit5.523%+2pp
Filing on EDGAR More quarters of JNJ

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters